NEW YORK, July 21, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2025.So What: If you purchased Capricor securities during the ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/capricor-loss-submission-form/?id=157205&from=3 CLASS PERIOD: October ...

ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors whi ...

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and s ...

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly providing misleading information regarding its lead drug candidate, deramiocel, leading to investor losses during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Capricor securities between October 9, 2024, and July 10, 2025 [1]. - Investors have until September 15, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Capricor - The complaint alleges that Capricor provided materially misleading information about deramiocel's potential to receive a Biologics License Application (BLA) approval from the FDA [3]. - It is claimed that while making positive statements, Capricor concealed adverse facts regarding the safety and efficacy data from its Phase 2 HOPE-2 trial [3]. Group 3: Impact of FDA Response - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [4]. - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025 [5].

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Capricor securities between October 9, 2024, and July 10, 2025 [2]. - The Complaint alleges that Capricor's safety and efficacy data from its Phase 2 HOPE-2 trial was inadequate for regulatory approval, and that the company's public statements regarding regulatory success were overly optimistic [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Capricor have until September 15, 2025, to request appointment as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that specializes in representing investors in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Capricor Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its lead drug candidate, deramiocel, and its regulatory status with the FDA [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Capricor between October 9, 2024, and July 10, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Capricor, with a deadline of September 15, 2025, for investors to seek the role of lead plaintiff [3][8]. - The complaint alleges that Capricor and its executives made false and misleading statements regarding the drug deramiocel and its FDA approval process [5]. Group 2: Regulatory Issues and Stock Performance - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, denying its Biologics License Application (BLA) due to insufficient evidence of effectiveness and the need for additional clinical data [6]. - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, indicating a significant market reaction to the news [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Capricor Therapeutics, Inc. for alleged misrepresentations regarding the safety and efficacy data of its lead drug candidate, deramiocel, during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Capricor's securities between October 9, 2024, and July 10, 2025 [1]. - The allegations focus on misrepresentations related to the four-year safety and efficacy data from the Phase 2 HOPE-2 trial of deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy [2]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file necessary documents by September 15, 2025, with the role involving representation of other class members in the litigation [3]. - Participation as a class member does not require serving as lead plaintiff, and all legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Group 1 - A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. for misleading investors regarding its lead cell therapy candidate, deramiocel, during the class period from October 9, 2024, to July 10, 2025 [1] - The lawsuit alleges that Capricor concealed adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial, while falsely suggesting they could obtain first approval for DMD cardiomyopathy [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied Capricor's Biologics License Application, the stock price fell from $11.40 to $7.64 per share [3] Group 2 - Investors who acquired shares of Capricor are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on September 15, 2025 [4]

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for allegedly misleading investors about the viability of its lead product candidate, deramiocel, during the class period from October 9, 2024, to July 10, 2025 [1][2]. Company Overview - Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the U.S. [1]. Allegations - The lawsuit claims that Capricor misled investors regarding the effectiveness of deramiocel for treating cardiomyopathy associated with DMD, creating a false impression of its approval prospects while concealing adverse safety and efficacy data from its Phase 2 HOPE-2 trial [2]. - On July 11, 2025, Capricor announced it received a Complete Response Letter (CRL) from the FDA, which denied its Biologics License Application, citing insufficient evidence of effectiveness and the need for additional clinical data [3]. Stock Impact - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, reflecting a significant decline in investor confidence [3].